文献速递糖尿病

基于特定临床场景的2型糖尿病以患者为中心的管理:系统评价、Meta分析与试验序贯分析

Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该系统评价与Meta分析纳入随访至少48周的随机对照试验,评估SGLT2抑制剂与GLP-1受体激动剂在老年、肥胖、ASCVD、冠心病、心衰或CKD等2型糖尿病亚组中的心血管与肾脏结局,结果显示两者在不同人群中减少心血管事件,试验序贯分析提示结论可靠。

要点

  • 肥胖和老年2型糖尿病患者中,GLP-1受体激动剂与3点主要不良心血管事件获益相关。
  • ASCVD患者中SGLT2抑制剂和GLP-1受体激动剂均与3点主要不良心血管事件获益相关。
  • 冠心病患者中仅SGLT2抑制剂与3点主要不良心血管事件获益相关。

核心结论

  • SGLT2抑制剂和GLP-1受体激动剂在特定人群中减少心血管事件:SGLT2抑制剂在既往冠心病、ASCVD和心衰患者中减少事件,GLP-1受体激动剂在ASCVD、老年和肥胖患者中减少心血管事件。
  • 试验序贯分析显示这些发现是确定的,本综述为2型糖尿病的循证个体化治疗开辟了路径。

研究设计与样本

  • 系统评价与Meta分析,纳入随机对照试验并进行试验序贯分析,方案注册号PROSPERO CRD42019132807。
  • 纳入标准为2型糖尿病患者属于以下亚组之一:老年、肥胖、既往动脉粥样硬化性心血管疾病、既往冠心病、既往心衰或既往慢性肾脏病,且随访至少48周。
  • 结局包括3点主要不良心血管事件、心血管死亡、心衰住院和肾脏结局;采用直接Meta分析计算干预组与对照组的事件相对风险。

主要发现

  • SGLT2抑制剂和GLP-1受体激动剂是唯一与不同人群心血管事件减少相关的降糖药物。
  • 肥胖和老年人群中,GLP-1受体激动剂与3点主要不良心血管事件获益相关;ASCVD患者中SGLT2抑制剂和GLP-1受体激动剂均与3点主要不良心血管事件获益相关;冠心病患者中仅SGLT2抑制剂与获益相关。
  • SGLT2抑制剂在既往冠心病、ASCVD和心衰患者中减少事件;GLP-1受体激动剂在ASCVD、老年和肥胖患者中减少心血管事件。
  • 试验序贯分析显示上述发现是确定的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: New antihyperglycemic medications have been proven to have cardiovascular (CV) and renal benefits in type 2 diabetes mellitus (T2DM); however, an evidence-based decision tree in specific clinical scenarios is lacking. MATERIALS AND METHODS: Systematic review and meta-analysis of randomized controlled trials (RCTs), with trial sequential analysis (TSA). Randomized controlled trial inclusion criteria were patients with T2DM from 1 of these subgroups: elderly, obese, previous atherosclerotic CV disease (ASCVD), previous coronary heart disease (CHD), previous heart failure (HF), or previous chronic kidney disease (CKD). Randomized controlled trials describing those subgroups with at least 48 weeks of follow-up were included. Outcomes: 3-point major adverse cardiovascular events (MACE), CV death, hospitalization due to HF, and renal outcomes. We performed direct meta-analysis with the number of events in the intervention and control groups in each subset, and the relative risk of the events was calculated. RESULTS: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA) were the only antihyperglycemic agents related to a reduction in CV events in different populations. For obese and elderly populations, GLP-1 RA were associated with benefits in 3-point MACE; for patients with ASCVD, both SGLT2i and GLP-1 RA had benefits in 3-point MACE, while for patients with CHD, only SGLT2i were beneficial. CONCLUSIONS: SGLT2i and GLP-1 RA reduced CV events in selected populations: SGLT2i led to a reduction in events in patients with previous CHD, ASCVD, and HF. GLP-1 RA led to a reduction in CV events in patients with ASCVD, elderly patients, and patients with obesity. Trial sequential analysis shows that these findings are conclusive. This review opens a pathway towards evidence-based, personalized treatment of T2DM. REGISTRATION: PROSPERO CRD42019132807.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Pinto LC, Rados DV, Remonti LR, et al. Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis. J Clin Endocrinol Metab. 2020. PMID: 32797182. doi:10.1210/clinem/dgaa534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。